Related Experiment Video
Updated: Apr 26, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Abstract:
In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and stem cells. Their work provides a rationale for the treatment of patients suffering from myeloproliferative neoplasms (MPNs).
Insights
This study shows that combining an MDM2 antagonist (RG7112) with pegylated interferon α (Peg-IFNα 2a) effectively targets cancer stem cells. This combination therapy offers a new treatment strategy for myeloproliferative neoplasms (MPNs).
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Myeloproliferative neoplasms (MPNs) are a group of blood cancers.
- The JAK2V617F mutation is a common driver in MPNs.
- Targeting hematopoietic stem cells is crucial for effective MPN treatment.
Purpose of the Study:
- To investigate the synergistic effects of an MDM2 antagonist and Peg-IFNα 2a in targeting JAK2V617F+ cells.
- To provide a rationale for combination therapy in MPNs.
Main Methods:
- Utilized an orally bioavailable MDM2 antagonist (RG7112).
- Administered pegylated interferon α (Peg-IFNα 2a).
- Focused on targeting JAK2V617F hematopoietic progenitors and stem cells.
Main Results:
- Demonstrated cooperation between RG7112 and Peg-IFNα 2a.
- Showed effective targeting of JAK2V617F hematopoietic stem cells.
- Established a potential therapeutic strategy for MPNs.
Conclusions:
- Combination therapy with an MDM2 antagonist and Peg-IFNα 2a is a promising approach for MPNs.
- This strategy targets key cells driving MPN.
- Further clinical investigation is warranted.
More Related Videos
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules
Treatment Resistant Cancers

